Understanding how integrins affect blood vessel function in Alzheimer's disease
Integrin regulation of vascular function in Alzheimer's disease
This study is looking at how a specific protein called CD49a affects blood vessels and the blood-brain barrier in people with Alzheimer's disease, hoping to find new ways to help improve brain health and slow down memory loss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10901016 on NIH RePORTER |
What this research studies
This research investigates the role of integrins, specifically CD49a, in regulating blood vessel and blood-brain barrier function in Alzheimer's disease. By examining how CD49a expression in endothelial cells influences vascular health and cognitive decline, the study aims to uncover the molecular mechanisms that contribute to Alzheimer's pathology. The research will utilize pre-clinical models to explore the relationship between integrins, vascular dysfunction, and neuroinflammation, providing insights into potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive impairment.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving vascular function and cognitive outcomes in patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown that targeting vascular dysfunction in Alzheimer's disease can lead to meaningful improvements, suggesting that this approach may hold promise.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Louveau, Antoine — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Louveau, Antoine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.